Antibodies News and Research

RSS

Pfizer/BioNTech COVID-19 vaccine candidate BNT162b2 profiled for large scale clinical trials

Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.

23 Aug 2020

Raccoon dogs potential intermediate host for SARS-CoV-2

Researchers at the Friedrich Loeffler Institute in Germany have conducted a study demonstrating that raccoon dogs were a potential intermediate host in the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Aug 2020

Nasal vaccine effective in preventing COVID-19 infection in mice

Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.

21 Aug 2020

Researchers find clues to successful immune response in the T cells of COVID-19 patients

When news about a novel coronavirus switched from a chronicle of its progress in China to headlines about a worldwide COVID-19 pandemic, Gladstone Institutes scientist Nadia Roan, PhD, was in the midst of publishing several papers on T cells and their role in HIV spread and long-lasting infections.

21 Aug 2020

VUMC receives $34 million grant for nationwide convalescent plasma study

Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of "convalescent plasma" as a treatment for COVID-19.

21 Aug 2020

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 presents a cynomolgus macaque model that develops symptomatic SARS-CoV-2 infection in a mild form, with low or no antibody responses, making it suitable to study human responses to vaccines and drugs targeting the virus.

21 Aug 2020

Study evaluates the reliability of new serological assays for detecting SARS-CoV-2 antibodies

Approximately four months after the initial description of cases of atypical pneumonia in Wuhan, China, in December 2019, COVID-19 had become a major pandemic threat.

20 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

COVID-19 linked to type 1 diabetes and diabetic ketoacidosis in children

A team of researchers at Imperial College Healthcare NHS Trust and Imperial College London has found a link between COVID-19 and new-onset type 1 diabetes in children. The research is published in the journal Diabetes Care.

20 Aug 2020

Canadian Coalition for COVID-19 releases 51 promising nanobodies

A group of Canadian companies has published 51 antibodies that show promising ability to bind the COVID-19 virus which could result in neutralizing the virus.

From SignalChem Biotech Inc. 20 Aug 2020

SARS-CoV-2 hijacks antiviral factors to promote infection in human lung cells

Now, a new study published in the preprint server bioRxiv in August 2020 shows that under conditions resembling those in vivo, IFNs may promote efficient viral invasion instead.

20 Aug 2020

Researchers develop vaccine for human herpesvirus 6B

A research group led by Professor MORI Yasuko (of the Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine) has revealed that the HHV-6B glycoprotein complex gH/gL/gQ1/gQ2 is an effective vaccine candidate for human herpesvirus 6B (HHV-6B).

20 Aug 2020

Lab-on-a-chip technology detects COVID-19 antibody

A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.

20 Aug 2020

Breast milk is not a potential source of infection, indicates study

As the novel coronavirus continues to spread around the world, so do the concerns of breastfeeding mothers.Although there have been no documented cases to date of an infant contracting COVID-19 as a result of consuming infected breast milk, the critical question of whether there is potential for this form of transmission remains.

20 Aug 2020

Researchers identify mechanism that explains lower-quality immune response in COVID-19 patients

The release of massive amounts of proteins called cytokines can lead to some of the most severe symptoms of COVID-19.

20 Aug 2020

Cytokine storms may prevent the development of long-term immunity to SARS-CoV-2

Shiv Pillai, MD, PhD, investigator in the Ragon Institute of MGH, MIT and Harvard and professor at Harvard Medical School (HMS), recently published a paper in Cell showing that that high levels of some cytokines seen in COVID-19 patients, as part of a cytokine storm, may prevent the development of long-term immunity to SARS-CoV-2, the virus that causes COVID-19.

19 Aug 2020

Researchers use heparin to block co-receptor for SARS-CoV-2 infection

Researchers at the University of Amsterdam have conducted a study showing that heparan sulfate proteoglycans are important co-receptors that severe acute respiratory syndrome 2 (SARS-CoV-2) requires to infect host cells.

19 Aug 2020

New approach to chronic pain treatment could bring relief

Something like a quarter of the world's population suffers from chronic pain at some point in their lives. As opposed to acute pain - for example, the feeling after hitting your finger with a hammer - chronic pain may not even have a clear cause, and it can linger for years or lifetimes.

19 Aug 2020

Single-dose adenovirus-vectored vaccine protects mice against SARS-CoV-2

The researchers selected the human adenovirus type 5 on which to base their vaccine because this replication-defective vector had already been used in their Ebola vaccine, with an excellent safety and immunogenicity profile in a phase 1 trial. The current study aimed to produce a vaccine that could offer mucosal vaccination and enhanced protection against this respiratory virus.

19 Aug 2020

Winter is not the time to become complacent about COVID-19

We are delighted to see the reduction in the number of cases of SARS-CoV-2 infection occurring in the United Kingdom in recent weeks, with currently 1 in 1900 people in the UK having coronavirus infection.

19 Aug 2020